L. Edward Cannon, Ph.D. trained with Edgar Haber (Harvard), a pioneer in antibody structure/function, and has held staff and faculty positions at Harvard Medical School, Brandeis University, and the University of Massachusetts Medical School. He was a founder and CSO for Hygeia Sciences, developer of the First Response™ Home Pregnancy and Ovulation Predictor products, the first monoclonal antibody-based home diagnostic products, and led Hygeia’s Initial Public Offering (IPO). He was CEO of Protein Engineering Technology, developer of phage display technology, and led the merger of Protein Engineering with Biotage to form Dyax Corp, where he was President of Dyax’s Therapeutic and Diagnostics business unit and led Dyax’s Kalbitor™ biotherapeutic program and co-led the company’s IPO. Subsequent to Dyax he has participated as a founder, operating CEO, and/or a director of a number of early stage biotechnology companies including , Adipogenix (CEO), a small molecule discovery company focused on adipocyte biology acquired by OSI Pharmaceuticals/Astellas, Smart Cells Inc. (director), developer of a glucose responsive insulin acquired by Merck, Energesis Pharmaceuticals (director), developing brown fat recruiters for obesity and related metabolic disorders, Akston Biosciences (director) developing companion animal biotherapeutics, and Diamune Therapeutics (director) developing type 1 diabetes prevention and once-weekly insulin therapy.